Evidence map›Paper›PMID 25519995›Full record

ArticleJournal of the Royal Society, Interface2015

Analytical reduction of combinatorial complexity arising from multiple protein modification sites.

Marc R Birtwistle

Open access · bronzeAbstract read
In one paragraph

Article in Journal of the Royal Society, Interface, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Marc R BirtwistleDepartment of Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA marc.birtwistle@mssm.edu.
Icahn School of Medicine at Mount Sinai · US

Funding

System Biology Center in New YorkP50GM071558 · NIGMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI ZAPH, SUSANA NEVES · 2007 to 2017
$22.8M
Drug Combination Signatures for Prediction and Mitigation of ToxicityU54HG008098 · NHGRI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BIRTWISTLE, MARC R., SOBIE, ERIC A · 2014 to 2019
$11.8M
Predicting the Heterogeneity of Cell-Fate DecisionsR01GM104184 · NIGMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BIRTWISTLE, MARC R. · 2014 to 2018
$1.8M
NHGRI NIH HHS U54 HG008098NHGRI NIH HHS U54HG008098NIGMS NIH HHS P50 GM071558NIGMS NIH HHS R01 GM104184NIGMS NIH HHS R01GM104184
6 · The paper itself

Abstract

Combinatorial complexity is a major obstacle to ordinary differential equation (ODE) modelling of biochemical networks. For example, a protein with 10 sites that can each be unphosphorylated, phosphorylated or bound to adaptor protein requires 3(10) ODEs. This problem is often dealt with by making ad hoc assumptions which have unclear validity and disallow modelling of site-specific dynamics. Such site-specific dynamics, however, are important in many biological systems. We show here that for a common biological situation where adaptors bind modified sites, binding is slow relative to modification/demodification, and binding to one modified site hinders binding to other sites, for a protein with n modification sites and m adaptor proteins the number of ODEs needed to simulate the site-specific dynamics of biologically relevant, lumped bound adaptor states is independent of the number of modification sites and equal to m + 1, giving a significant reduction in system size. These considerations can be relaxed considerably while retaining reasonably accurate descriptions of the true system dynamics. We apply the theory to model, using only 11 ODEs, the dynamics of ligand-induced phosphorylation of nine tyrosines on epidermal growth factor receptor (EGFR) and primary recruitment of six signalling proteins (Grb2, PI3K, PLCγ1, SHP2, RasA1 and Shc1). The model quantitatively accounts for experimentally determined site-specific phosphorylation and dephosphorylation rates, differential affinities of binding proteins for the phosphorylated sites and binding protein expression levels. Analysis suggests that local concentration of site-specific phosphatases such as SHP2 in membrane subdomains by a factor of approximately 10(7) is critical for effective site-specific regulation. We further show how our framework can be extended with minimal effort to consider binding cooperativity between Grb2 and c-Cbl, which is important for receptor trafficking. Our theory has potentially broad application to reduce combinatorial complexity and allow practical simulation of a variety ODE models relevant to systems biology and pharmacology applications to allow exploration of key aspects of complexity that control signal flux.

Indexed as

Models, BiologicalAnimalsErbB ReceptorsGRB2 Adaptor ProteinHumansp120 GTPase Activating ProteinPhosphatidylinositol 3-KinasesPhospholipase C gammaPhosphorylationProtein Processing, Post-TranslationalProtein Tyrosine Phosphatase, Non-Receptor Type 11Proto-Oncogene Proteins c-cblShc Signaling Adaptor ProteinsSignal TransductionSrc Homology 2 Domain-Containing, Transforming Protein 1CBL protein, humanEGFR protein, humanErbB ReceptorsGRB2 Adaptor ProteinGRB2 protein, humanp120 GTPase Activating ProteinPhosphatidylinositol 3-KinasesPhospholipase C gammaProtein Tyrosine Phosphatase, Non-Receptor Type 11Proto-Oncogene Proteins c-cblRASA1 protein, humanSHC1 protein, humanShc Signaling Adaptor ProteinsSrc Homology 2 Domain-Containing, Transforming Protein 1combinatorial complexitykinetic modellingmodel reductionsignal transduction

Identifiers

PMID25519995
PMCPMC4305424
OpenAlexW2028959353

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.